| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 49 companies in the Life Sciences Tools & Services industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 15, 2022 | EXAS Exact Sciences Corp | Orville Jacob A76 | General Manager, New Ventures | Sell | 940 | $79.55 | $74,777.00 | -12.6% | -37.8% | -18.6% | |
| Feb 14, 2022 | OPK Opko Health, Inc. | Frost Phillip Md Et Al48 | CEO &Chairman | Buy | 100,000 | $3.04 | $303,568.53 | - | -1.7% | -60.6% | |
| Feb 14, 2022 | TMO Thermo Fisher Scientific Inc. | Manzi Jim P52 | Director | Sell | 1,500 | $563.95 | $845,925.00 | -8.4% | -3.8% | +2.1% | |
| Feb 11, 2022 | WGS Genedx Holdings Corp. | Assad Shawn82 | Chief Accounting Officer | Sell | 3,647 | $3.64 | $13,275.08 | -12.8% | -52.1% | -88.7% | |
| Feb 10, 2022 | GH Guardant Health, Inc. | Meresman Stanley J75 | Director | Sell | 4,934 | $73.80 | $364,129.20 | -54.9% | -60.9% | -62.0% | |
| Feb 10, 2022 | CSTL Castle Biosciences Inc | Bradbury Daniel69 | Director | Sell | 17,704 | $46.00 | $814,307.69 | -1.6% | -59.4% | -40.6% | |
| Feb 10, 2022 | WGS Genedx Holdings Corp. | Ro Isaac89 | Chief Financial Officer | Sell | 21,735 | $3.60 | $78,241.65 | -12.2% | -57.4% | -89.0% | |
| Feb 9, 2022 | CDNA Caredx, Inc. | Seeto Reginald76 | See Remarks | Sell | 2,550 | $45.00 | $114,758.93 | -1.3% | -49.3% | -66.0% | |
| Feb 9, 2022 | CDNA Caredx, Inc. | Goldberg Michael85 | Director | Sell | 500 | $42.96 | $21,480.00 | -0.8% | -49.3% | -66.0% | |
| Feb 7, 2022 | CDNA Caredx, Inc. | Maag Peter83 | Director | Sell | 10,000 | $42.07 | $420,668.28 | -1.5% | -47.5% | -61.3% | |
| Feb 4, 2022 | TWST Twist Bioscience Corp | Johannessen Jan71 | Director | Sell | 253 | $58.88 | $14,896.39 | -13.3% | -47.7% | -57.5% | |
| Feb 4, 2022 | TWST Twist Bioscience Corp | Chess Robert84 | Director | Sell | 253 | $58.88 | $14,896.39 | -0.5% | -47.7% | -57.5% | |
| Feb 4, 2022 | CDNA Caredx, Inc. | Seeto Reginald76 | See Remarks | Sell | 8,170 | $40.70 | $332,494.87 | -2.5% | -21.4% | -58.9% | |
| Feb 2, 2022 | DHR Danaher Corp /de/ | Ellis Brian W62 | Senior Vice President - GC | Sell | 5,365 | $293.99 | $1,577,247.77 | -30.2% | -15.5% | -7.8% | |
| Feb 1, 2022 | TWST Twist Bioscience Corp | Finn Patrick John73 | Chief Commercial Officer | Sell | 659 | $60.52 | $39,882.68 | -1.5% | -49.7% | -53.4% | |
| Feb 1, 2022 | OPK Opko Health, Inc. | Frost Phillip Md Et Al48 | CEO &Chairman | Buy | 150,000 | $3.03 | $455,009.25 | - | -8.5% | -54.9% | |
| Feb 1, 2022 | CDNA Caredx, Inc. | Seeto Reginald76 | See Remarks | Sell | 814 | $42.13 | $34,293.82 | -0.6% | -22.5% | -62.7% | |
| Jan 31, 2022 | DHR Danaher Corp /de/ | Weidemanis Joakim67 | Executive Vice President | Sell | 20,508 | $285.24 | $5,849,753.19 | -24.3% | -12.3% | -7.2% | |
| Jan 28, 2022 | PSNL Personalis, Inc. | Chen Richard70 | Chief Medical Officer | Sell | 705 | $9.93 | $7,000.65 | -0.4% | -44.3% | -77.0% | |
| Jan 28, 2022 | WGS Genedx Holdings Corp. | Schadt Eric62 | Chief Executive Officer | Sell | 29,100 | $2.84 | $82,667.28 | -22.5% | -26.4% | -86.3% | |
| Jan 28, 2022 | WGS Genedx Holdings Corp. | Saad Kareem61 | Chief Business Officer | Sell | 6,697 | $2.84 | $19,026.18 | -11.3% | -26.4% | -86.3% | |
| Jan 28, 2022 | WGS Genedx Holdings Corp. | White Karen Ann77 | Chief People Officer | Sell | 1,776 | $2.84 | $5,046.15 | -21.6% | -26.4% | -86.3% | |
| Jan 28, 2022 | PSNL Personalis, Inc. | Tachibana Aaron68 | Chief Financial Officer | Sell | 705 | $9.93 | $7,000.65 | -0.3% | -44.3% | -77.0% | |
| Jan 28, 2022 | WGS Genedx Holdings Corp. | Clark Daniel Emmett85 | Secretary And General Counsel | Sell | 1,512 | $2.84 | $4,297.56 | -0.5% | -26.4% | -86.3% | |
| Jan 28, 2022 | WGS Genedx Holdings Corp. | Prentice Anthony85 | Chief Product Officer | Sell | 2,021 | $2.84 | $5,742.67 | -21.0% | -26.4% | -86.3% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.